Why the study?
Fast viral replication and a 7-day delay to achieve vaccine-induced protection limit control of foot-and-mouth disease, creating a need for new fast-acting antiviral strategies to boost host innate immunity.
Do interferon-based biotherapeutics reduce Foot-and-Mouth Disease Virus replication in susceptible livestock species?
Do interferon-based biotherapeutics reduce Foot-and-Mouth Disease Virus replication in susceptible livestock species?
Answers are grounded in this paper and cite their sources.
IFN-based biotherapeutics represent a promising fast-acting antiviral strategy to control FMDV outbreaks in livestock prior to the onset of vaccine-induced immunity.
Foot-and-mouth disease (FMD) is a highly contagious vesicular disease of cloven-hoofed animals that severely constrains international trade of livestock and animal products. Currently, disease control measures include broad surveillance, enforcement of sanitary policy, and use of an inactivated vaccine. While use of these measures has contributed to eliminating foot-and-mouth disease virus (FMDV) from a vast area of the world, the disease remains endemic in three continents, and outbreaks occasionally appear in previously declared FMD-free zones, causing economic and social devastation. Among others, a very fast rate of viral replication and the need for 7 days to achieve vaccine-induced protection are the main limitations in controlling the disease. New fast-acting antiviral strategies targeted to boost the innate immunity of the host to block viral replication are needed. Here we review the knowledge on the multiple strategies FMDV has evolved to block the host innate immunity, with particularly focus on the past and current research toward the development of interferon (IFN)-based biotherapeutics in relevant livestock species.
No takes yet. Share an insight, caveat, or question.
Medina et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: